Akero Therapeutics Inc. (NASDAQ:AKRO) shares traded -6.70% lower at $43.85 on Wall Street last session.
In accordance with the data, 6 analysts cover Akero Therapeutics Inc. (NASDAQ:AKRO). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $65.00 and a low of $48.00, we find $55.00. Given the previous closing price of $47.00, this indicates a potential upside of 17.02 percent. AKRO stock price is now -6.58% away from the 50-day moving average and 45.54% away from the 200-day moving average. The market capitalization of the company currently stands at $2.03B.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
It has been rated a hold by 0 analysts and a buy by 6. Brokers who have rated the stock have averaged $56.17 as their price target over the next twelve months.
With the price target enhanced from $40 to $65, Morgan Stanley Upgraded its rating from Equal-Weight to Overweight for Akero Therapeutics Inc. (NASDAQ: AKRO). On September 14, 2022, Evercore ISI Upgraded its previous ‘In-line’ rating to ‘Outperform’ on the stock increasing its target price from $10 to quote $50, while ‘Morgan Stanley’ rates the stock as ‘Equal-Weight’.
In other news, Cheng Andrew, President & CEO sold 25,000 shares of the company’s stock on Mar 01. The stock was sold for $1,166,338 at an average price of $46.65. Upon completion of the transaction, the President & CEO now directly owns 370,999 shares in the company, valued at $16.27 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 01, President & CEO Cheng Andrew sold 25,000 shares of the business’s stock. A total of $1,226,395 was realized by selling the stock at an average price of $49.06. This leaves the insider owning 370,999 shares of the company worth $16.27 million. Insiders disposed of 2,452,014 shares of company stock worth roughly $107.52 million over the past 1 year. A total of 2.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in AKRO stock. A new stake in Akero Therapeutics Inc. shares was purchased by MILLENNIUM MANAGEMENT LLC during the first quarter worth $10,832,000. ARTISAN PARTNERS LIMITED PARTNERSHIP invested $10,457,000 in shares of AKRO during the first quarter. In the first quarter, HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND acquired a new stake in Akero Therapeutics Inc. valued at approximately $10,261,000. VOLORIDGE INVESTMENT MANAGEMENT, LLC acquired a new stake in AKRO for approximately $9,606,000. PUBLIC SECTOR PENSION INVESTMENT BOARD purchased a new stake in AKRO valued at around $9,384,000 in the second quarter.
Akero Therapeutics Inc. (NASDAQ: AKRO) opened at $47.18 on Thursday. During the past 12 months, Akero Therapeutics Inc. has had a low of $7.52 and a high of $54.88. As of last week, the company has a debt-to-equity ratio of 0.03, a current ratio of 15.00, and a quick ratio of 15.00. The fifty day moving average price for AKRO is $46.94 and a two-hundred day moving average price translates $30.13 for the stock.
The latest earnings results from Akero Therapeutics Inc. (NASDAQ: AKRO) was released for Sep, 2022.
Akero Therapeutics Inc.(AKRO) Company Profile
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company’s lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
